A Celltrion-backed biotech is developing 'tunable' conjugates to crack solid tumors — and it has eyes on the clinic
The next generation of antibody-drug conjugates has become a big area of focus in oncology venture capital, with a slate of biotechs arguing they have the best linkers and payloads to get the job done. Now, an outfit backed by Korean giant Celltrion is ready to test its own mix in the clinic.
Newcastle, UK-based Iksuda Therapeutics has closed a $47 million financing round, which the biotech will use to walk its pipeline of antibody-drug conjugates into the clinic, the company said Sunday. The round was led by Korea’s Mirae Capital with participation from Celltrion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
